The recent AI-based discovery of broad-spectrum antibiotic candidates highlights the potential of new machine learning methods to find compounds humans might otherwise miss, but ups the ante on the quality and diversity of input data...

DISEASE CATEGORY: Cancer INDICATION: Lung cancer Patient sample, cell culture and mouse studies suggest dual activation of JNK1 and JNK2 could help treat STK11-deficient squamous cell carcinoma (SCC) of the lung. In patients, low tumor...

Auris Medical Holding AG (NASDAQ:EARS) reported additional data from the Phase III HEALOS trial evaluating single intratympanic doses of 0.4 and 0.8 mg/mL brimapitide (AM-111, D-JNKI-1, XG-102) gel in 256 patients with severe to profound...

In a paper published in Nature Medicine , researchers at Wuhan University and Weill Cornell Medicine found that increasing expression of the deubiquitinating enzyme cylindromatosis turban tumor syndrome (CYLD) reversed progression of non-alcoholic steatohepatitis (NASH) in...

Auris Medical Holding AG (NASDAQ:EARS) stock fell 49% Nov. 28 after the company said brimapitide (AM-111) missed the primary endpoint in the Phase III HEALOS trial. Neither tested dose of intratympanic brimapitide gel significantly improved...

Auris Medical Holding AG (NASDAQ:EARS) fell $0.40 (49%) to $0.42 Tuesday after it said brimapitide (AM-111) missed the primary endpoint in the Phase III HEALOS trial. Neither tested dose of intratympanic brimapitide gel significantly improved...

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since...

Two studies by Genentech have shown DLK inhibition is neuroprotective in two chronic neurodegenerative diseases and suggest the target may play a broad role in driving neurodegeneration, regardless of the underlying cause. MAP kinase kinase...

A three-way deal between Amgen Inc. , Feldan Therapeutics Inc. and Elasmogen Ltd. is the latest cause for optimism that technologies are finally converging to enable the generation of cell-penetrating biologics. The biotechs join a small...

Based on unmet need alone, hearing loss should have been every bit as attractive to investors and drug developers as ophthalmic diseases, which entered a renaissance in the mid-2000s resulting in a multibillion-dollar market for...